InMed Pharmaceuticals Inc
INM
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.33M
Close$
$5.56
334.7% upside
Current Fair Value
334.7% upsideUndervalued by 334.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.33 Million |
|---|---|
| Enterprise Value | $-2,192,078,195.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-3.12 |
| Beta | 0.98 |
| Outstanding Shares | 4,373,290 |
Return
| Return on Equity | -126.94% |
|---|---|
| Return on Assets | -45.04% |
| Return on Invested Capital | -131.51% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | 0 |
| Price to Sales | 0.0 |
| Price to Book Ratio | 0.01 |
| Enterprise Value to Revenue | -0.47 |
| Enterprise Value to EBIT | 1.55 |
| Enterprise Value to Net Income | 1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 18, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
September 18, 2026
EPS Estimate
$-94.44
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About InMed Pharmaceuticals Inc
20 employees
CEO: Eric Adams InMed Pharmaceuticals is a clinical-stage company developing a pipeline of cannabinoid-based pharmaceutical drug candidates, initially focused on the therapeutic benefits of cannabinol ('CBN'), in diseases with high unmet medical need. T...